Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 3Nasopharyngeal Carcinoma 2Carcinoma 2Renal Pelvis and Ureter Urothelial Carcinoma 1Osteosarcoma 1NSCLC 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gallbladder Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Squamous Cell 1

Interventions

Doxorubicin 3Methotrexate 2Cisplatin 2merphos 1cabozantinib 1apatinib 1Zoledronic Acid 1X-Rays 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Platinum 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Ifosfamide 1Drug Therapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Osteosarcoma × Platinum × Clear all
NCT05691478 2026-05-27

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

Phase 2/3 Recruiting
1,122 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡